Saturday, March 21, 2015 3:15:14 PM
It is way too early to suggest CTIX is being overlooked or not getting respect. I assert that the opposite is in fact true based upon the facts. The Brilacidin P2b clinical trial has just concluded. This is Cellceutix's first completed mid-stage Clinical Trial. Full results have yet to be presented, waiting to make a bigger splash at the ECCMID2015 and in the post P2b meeting with the FDA.
Planning is underway for pivotal Phase 3 clinical trials which will be presented to the FDA, along with likely requests for advantages related to the FDA QIDP designation.
The facts indicate CTIX is being noticed and respected:
1. The CEO Leo Ehrlich has already indicated that they are fielding frequent Brilacidin inquires.
2. The CEO expects the best offers to come once the Phase 3 trial is more advanced in planning, underway, or even concluded.
3. The CEO indicated he would consider an offer now premature, and would only entertain one if it was "spectacular". (Even so, there would be a period of negotiations and approvals which could be happening already.)
4. Phase-2b Clinical Trial of Brilacidin Accepted for Oral Presentation at the European Congress of Clinical Microbiology and Infectious Diseases One of the most prestigious venues to release clinical trial results.
5. Cellceutix Signs Material Transfer Agreements for Defensin Mimetic Compounds With Leading Universities. With Fox Chase grant research ongoing for several promising Brilacidin analogs, with some additional results expected in the coming weeks.
6. Cellceutix Brilacidin Receives QIDP Designation From the FDA
7. Cellceutix has signed an agreement with a division of one of the largest U.S. pharmaceutical companies for testing Brilacidin as a component of certain implanted devices as a means to prevent infection.
8. FDA approval for a Phase 2 Clinical Trial of Brilacidin-Om for Oral Mucositis, active and planned at the leading cancer research center MD Anderson.
All of this, and more I haven't detailed, just over a year since Cellceutix acquired Brilacidin. That is extremely fast for the bio-tech industry.
Alternatively the suggestion that CTIX is being overlooked or not getting respect because events have not yet happened which the CEO has clearly indicated are premature?
I'd say a bit of re-evaluation of this viewpoint is required here. A bit of patience is required also. Yes I know, difficult for us shareholders who want to win yesterday. But the obvious facts indicate:
Cellceutix is getting a great deal of respect and recognition, and it is still early days with the Brilacidin trial not yet presented or the FDA meeting having occurred.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM